Squarepoint Ops LLC Raises Position in Solventum Corporation $SOLV

Squarepoint Ops LLC boosted its position in shares of Solventum Corporation (NYSE:SOLV) by 6,103.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 243,128 shares of the company’s stock after buying an additional 239,209 shares during the period. Squarepoint Ops LLC owned 0.14% of Solventum worth $18,757,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 19.0% during the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of Solventum by 5,434.1% in the second quarter. California State Teachers Retirement System now owns 13,234,928 shares of the company’s stock valued at $1,021,075,000 after purchasing an additional 12,995,776 shares during the last quarter. State Street Corp lifted its position in Solventum by 2.0% during the fourth quarter. State Street Corp now owns 6,344,761 shares of the company’s stock worth $502,759,000 after buying an additional 124,490 shares in the last quarter. Boston Partners boosted its stake in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Solventum by 20.0% in the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after buying an additional 763,308 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on SOLV. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. BTIG Research lifted their target price on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Piper Sandler lifted their target price on shares of Solventum from $92.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Mizuho set a $113.00 price target on shares of Solventum in a research note on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research report on Saturday, August 22nd. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Solventum currently has an average rating of “Moderate Buy” and an average target price of $91.64.

Solventum Stock Performance

Shares of SOLV stock opened at $90.13 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $94.16. The stock has a market capitalization of $15.34 billion, a PE ratio of 11.02, a P/E/G ratio of 1.41 and a beta of 0.61. The firm has a 50 day moving average of $84.77 and a two-hundred day moving average of $76.37.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter last year, the company earned $1.69 EPS. Solventum’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, research analysts predict that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation (NYSE:SOLV) is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.